康希诺生物

2024

02

Obtained the Acceptance Notice of drug registration applications for the PCV13i、DTcP Infant
03

Initiated Phase Ⅲ clinical trial for Absorbed Tetanus Vaccine
04

Received positive preliminary results from Phase I clinical trials of the PBPV
05

Obtained clinical trial approval of the Hib Vaccine
06

MCV4 has received the drug registration certificate granted in Indonesia
10

VLP-Polio received further funding from the Bill & Melinda Gates Foundation, and initiated clinical trial in Australia (Phase I) and Indonesia (Phase I / II)
10

Collaborate with the National Institutes of Biotechnology Malaysia to develop the multivalent influenza mRNA vaccine
11

Obtained the Acceptance Notice of supplemental application to expand the MCV4‘s applicable population to children aged from 3 months to 6 years old (83 months)
12

Initiated phase Ⅱ/Ⅲ clinical trial for the Tdcp Adolescent and Adult

2023

03

IM & IH of Zoster Vaccine approved for clinical trial in Canada
05

Subscription Agreement with Solution Group Berhad
06

Initiated Phase Ⅰb clinical trial for PBPV
07

Bivalent COVID-19 mRNA vaccine, Tdcp Adolescent and Adult, and Tetanus vaccine approved for clinical trial
08

DTcP Infant vaccine entered Phase Ⅲ clinical trial

2022

01

The Recombinant Novel Coronavirus vaccine Convidecia® approved as heterologous booster in China
02

The WHO granted the Emergency Use Listing for the Recombinant Novel Coronavirus
04

The world's first inhaled COVID-19 vaccine Convidecia Air® approved as heterologous booster in China

2021

01

The Recombinant Novel Coronavirus Vaccine Convidecia® received approval in over 10 countries
02

Menphecia® approved in China
03

Menhycia® approved in China

2020

01

Listed on the Sci-Tech Innovation Board of SSE
02

Completed Convidecia® phase II clinical trial, and launched multi-center phase I

2019

2018

2017

2016

2015

2014

2012

2011

2009